Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective
- PMID: 34343613
- DOI: 10.1016/j.jhep.2021.07.027
Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective
Abstract
Antibody-mediated rejection after liver transplantation is an under-recognised cause of allograft injury. While definitions of acute and chronic antibody-mediated rejection have increased clinical awareness, timely identification and management of antibody-mediated rejection remain difficult because of complexities in diagnosis and histopathology, lack of treatment protocols, and unclear long-term outcomes. While recent cohort studies assessing the importance of donor-specific antibodies have aided in its diagnosis, literature on the treatment of antibody-mediated rejection in liver transplantation remain limited to case reports and small series. Further increasing the awareness and timely recognition of antibody-mediated rejection post-liver transplantation is crucial in order to stimulate future research and the development of protocols for its diagnosis and treatment. This review will summarise recent advances in the clinical diagnosis and treatment of antibody-mediated rejection in liver transplantation, as well as some of the histopathologic features (on liver biopsy tissue) of acute and chronic antibody-mediated rejection.
Keywords: HLA; antibody-mediated rejection; donor-specific antibody; histology; liver transplantation.
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest There are no conflicts of interest (including personal or financial) to declare from all of the authors. Writing Assistance: None. There is no shared data present in this manuscript. Please refer to the accompanying ICMJE disclosure forms for further details.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
